Opus Genetics officer reports automatic tax share sale

Opus Genetics, Inc. executive Amy Zaremba Rabourn, Head of Financial Quality Assurance, reported an automatic sale of 2,816 shares of common stock at $5.245 per share.

Accepted by SEC EDGAR 03/18/2026 - 04:11 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Opus Genetics, Inc. executive Amy Zaremba Rabourn, Head of Financial Quality Assurance, reported an automatic sale of 2,816 shares of common stock at $5.245 per share. The shares were sold by the company to satisfy tax withholding obligations from a restricted stock unit vesting event, and the filing states this was not a discretionary trade. After this transaction, she directly holds 190,312 shares of common stock.

Insider Trade Summary

Net Seller: 2,816 shares

Net Sell 1 txn

Insider Zaremba Rabourn Amy

Role Head of Fin. Quality Assurance

Sold 2,816 shs ($15K)

Share of Position Sold 1.5%

Type	Security	Shares	Price	Value
Sale	Common Stock	2,816	$5.245	$15K

Holdings After Transaction: Common Stock — 190,312 shares (Direct)

Holdings Before and After: Common Stock, 193,128 to 190,312 shares (Direct)

Other Insiders: 3 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (1)

1. F1. The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Opus Genetics (IRD) report for Amy Zaremba Rabourn?

Opus Genetics reported an automatic sale of 2,816 common shares for Amy Zaremba Rabourn. The shares were sold at $5.245 each to cover tax withholding from a restricted stock unit vesting, according to the filing footnote.

Was the Opus Genetics (IRD) share sale by Amy Zaremba Rabourn discretionary?

No, the filing states the sale did not represent a discretionary trade by Amy Zaremba Rabourn. The company automatically sold shares on her behalf solely to satisfy tax withholding obligations tied to a restricted stock unit vesting and settlement event.

How many Opus Genetics (IRD) shares does Amy Zaremba Rabourn hold after the transaction?

After the reported transaction, Amy Zaremba Rabourn directly holds 190,312 shares of Opus Genetics common stock. This context shows the 2,816 shares sold for tax withholding represent a relatively small portion of her overall reported equity position.

What price was received for the Opus Genetics (IRD) shares sold in this Form 4?

The 2,816 Opus Genetics common shares were sold at a price of $5.245 per share. This price applies to the automatic sale executed to cover tax withholding obligations arising from the vesting and settlement of a restricted stock unit award.

What role does Amy Zaremba Rabourn hold at Opus Genetics (IRD)?

Amy Zaremba Rabourn is identified as an officer of Opus Genetics, serving as Head of Financial Quality Assurance. Her position is noted in the Form 4, which reports the automatic tax-related share sale and her resulting direct ownership of 190,312 common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zaremba Rabourn Amy

(Last) (First) (Middle)

C/O OPUS GENETICS, INC.

8 DAVIS DRIVE, SUITE 220

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Opus Genetics, Inc. [ IRD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Head of Fin. Quality Assurance

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/16/2026		S(1)		2,816	D	$5.245	190,312	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person.

	/s/ Amy Rabourn	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)